Published in Scand J Urol on September 19, 2012
Improving bladder cancer imaging using 3-T functional dynamic contrast-enhanced magnetic resonance imaging. Invest Radiol (2014) 0.83
PET/CT versus conventional CT for detection of lymph node metastases in patients with locally advanced bladder cancer. BMC Urol (2015) 0.76
Current Staging Procedures in Urinary Bladder Cancer. Diagnostics (Basel) (2013) 0.75
Current Concepts in the Management of Muscle Invasive Bladder Cancer. Indian J Surg Oncol (2016) 0.75
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 5.44
The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res (2008) 4.63
Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. J Exp Med (2008) 3.74
Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol (2009) 2.80
The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol (2007) 2.77
Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol (2010) 2.49
A molecular taxonomy for urothelial carcinoma. Clin Cancer Res (2012) 2.37
IRF4 transcription-factor-dependent CD103(+)CD11b(+) dendritic cells drive mucosal T helper 17 cell differentiation. Immunity (2013) 2.27
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst (2002) 2.25
MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer (2009) 2.06
Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res (2010) 1.99
Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res (2002) 1.93
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res (2007) 1.91
Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics (2007) 1.71
Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer? World J Surg (2010) 1.68
Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res (2003) 1.65
Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol (2010) 1.57
Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One (2012) 1.56
Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res (2007) 1.54
Treatment delay and prognosis in invasive bladder cancer. J Urol (2005) 1.53
Quality of life after cystectomy and urinary diversion: an evidence based analysis. J Urol (2005) 1.53
ICUD-EAU International Consultation on Bladder Cancer 2012: Non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol (2012) 1.43
ICUD-EAU International Consultation on Bladder Cancer 2012: Urinary diversion. Eur Urol (2012) 1.42
CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma (2010) 1.41
Simplified intraoperative sentinel-node detection performed by the urologist accurately determines lymph-node stage in prostate cancer. Scand J Urol (2014) 1.38
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat (2013) 1.38
Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Cancer Res (2005) 1.34
CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers. BMC Cancer (2011) 1.31
Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes. Mol Oncol (2012) 1.24
Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors. BMC Med Genomics (2008) 1.24
A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS One (2011) 1.21
Dose-volume relationships between enteritis and irradiated bowel volumes during 5-fluorouracil and oxaliplatin based chemoradiotherapy in locally advanced rectal cancer. Acta Oncol (2007) 1.18
Molecular profiling reveals low- and high-grade forms of primary melanoma. Clin Cancer Res (2012) 1.17
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat (2007) 1.14
Prognostic impact of array-based genomic profiles in esophageal squamous cell cancer. BMC Cancer (2008) 1.12
Knowledge about hereditary nonpolyposis colorectal cancer; mutation carriers and physicians at equal levels. BMC Med Genet (2009) 1.10
The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer. Mod Pathol (2009) 1.07
Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer. Breast Cancer Res Treat (2009) 1.07
DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status. Epigenetics (2012) 1.07
Nuclear Janus-activated kinase 2/nuclear factor 1-C2 suppresses tumorigenesis and epithelial-to-mesenchymal transition by repressing Forkhead box F1. Cancer Res (2010) 1.05
Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol (2007) 1.04
Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol (2013) 1.03
Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years' follow-up. Breast Cancer Res Treat (2013) 1.02
Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer--clinical associations and reasons for discrepancies. Acta Oncol (2003) 1.02
Lymph node metastasis in bladder cancer. Eur Urol (2005) 1.02
Bladder cancers respond to intravesical instillation of HAMLET (human alpha-lactalbumin made lethal to tumor cells). Int J Cancer (2007) 1.00
Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med (2002) 0.99
Distinct mitotic segregation errors mediate chromosomal instability in aggressive urothelial cancers. Clin Cancer Res (2007) 0.99
Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin? Lab Invest (2009) 0.98
Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1. Cancer Genet Cytogenet (2007) 0.98
Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies. BMC Cancer (2011) 0.98
Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial. Eur J Cancer (2009) 0.95
The nested variant of urothelial carcinoma: a rare but important bladder neoplasm with aggressive behavior. Three case reports and a review of the literature. Urol Oncol (2003) 0.94
Intraoperative sentinel node detection improves nodal staging in invasive bladder cancer. J Urol (2006) 0.94
A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: the women's health in the Lund area (WHILA) study (Sweden). Cancer Causes Control (2003) 0.94
Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer (2002) 0.94
Genome-wide search for breast cancer linkage in large Icelandic non-BRCA1/2 families. Breast Cancer Res (2010) 0.93
Immunohistochemical patterns in rectal cancer: application of tissue microarray with prognostic correlations. Int J Cancer (2004) 0.93
Diagnostic delay and prognosis in invasive bladder cancer. Scand J Urol Nephrol (2003) 0.92
Improved prognostication in soft tissue sarcoma: independent information from vascular invasion, necrosis, growth pattern, and immunostaining using whole-tumor sections and tissue microarrays. Hum Pathol (2005) 0.92
Estrogen and progesterone receptor assay in paraffin-embedded breast cancer--reproducibility of assessment. Acta Oncol (2003) 0.90
The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer. PLoS One (2013) 0.90
Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol Oncol (2007) 0.90
Incontinent urinary diversion. BJU Int (2008) 0.90
Expression profiling using tissue microarray in 211 malignant fibrous histiocytomas confirms the prognostic value of Ki-67. Virchows Arch (2004) 0.89
Recurrent and multiple bladder tumors show conserved expression profiles. BMC Cancer (2008) 0.89
High tumor tissue concentration of plasminogen activator inhibitor 2 (PAI-2) is an independent marker for shorter progression-free survival in patients with early stage endometrial cancer. Int J Cancer (2002) 0.88
Reproducibility of human epidermal growth factor receptor 2 analysis in primary breast cancer: a national survey performed at pathology departments in Sweden. Acta Oncol (2009) 0.88
Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer. Breast (2008) 0.88
Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study. BMC Cancer (2012) 0.87
Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients. Thromb Haemost (2003) 0.87
Novel set of multiplex assays (SalPrint15) for efficient analysis of 15 microsatellite loci of contemporary samples of the Atlantic salmon (Salmo salar). Mol Ecol Resour (2009) 0.87
Patient-assessed outcomes in Swedish and Egyptian men undergoing radical cystectomy and orthotopic bladder substitution--a prospective comparative study. Urology (2007) 0.87
A novel model for Ki67 assessment in breast cancer. Diagn Pathol (2014) 0.86
Prediction of outcome after diagnosis of metachronous contralateral breast cancer. BMC Cancer (2011) 0.86
Mapping of a novel ocular and cutaneous malignant melanoma susceptibility locus to chromosome 9q21.32. J Natl Cancer Inst (2005) 0.86
Training artificial neural networks directly on the concordance index for censored data using genetic algorithms. Artif Intell Med (2013) 0.86
Pelvic exenteration for advanced and recurrent malignancy. World J Surg (2010) 0.86
Can tissue microarray-based analysis of protein expression predict recurrence of stage Ta bladder cancer? Scand J Urol Nephrol (2011) 0.86
Ezrin expression predicts local recurrence and development of metastases in soft tissue sarcomas. J Clin Pathol (2011) 0.86